Mazapertine
Alternative Names: RWJ 37796Latest Information Update: 22 Jan 2001
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Antipsychotics; Piperazines
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 22 Jan 2001 No-Development-Reported for Schizophrenia in European Union (PO)
- 22 Jan 2001 No-Development-Reported for Schizophrenia in USA (PO)
- 18 Jun 1997 Phase-II clinical trials for Schizophrenia in European Union (PO)